Virtus Biotech ETF
14 hedge funds and large institutions have $5.22M invested in Virtus Biotech ETF in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
17% more capital invested
Capital invested by funds: $4.45M → $5.22M (+$768K)
16.78% more ownership
Funds ownership: 0% → 16.78% (+17%)
8% more funds holding
Funds holding: 13 → 14 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.58M |
| 2 |
LPL Financial
San Diego,
California
|
+$165K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$127K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$100K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$950K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$611K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
BBP Hedge Fund Activity: Q4 2016 in Review
14 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2016, worth a combined $5.22M — up 17% from $4.45M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBP positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $1.58M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $950K sold.
- 14 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2016, up from 13 in Q3 2016.
- Funds reported $5.22M of Virtus Biotech ETF stock for Q4 2016, up 17% quarter-over-quarter.
- 4 funds opened new Virtus Biotech ETF positions in Q4 2016 and 3 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q4 2016 was Royal Bank of Canada, an estimated $1.58M added.
- The largest Virtus Biotech ETF seller in Q4 2016 was Susquehanna International Group, an estimated $950K sold.
Based on aggregated 13F filings for Q4 2016.